GIOCOV

GIOCOV is a UK-incorporated biotechnology company launched in 2021 as a wholly owned subsidiary of GIOSTAR to pursue stem cell-based treatments for COVID-19 and Long COVID. The company appears focused on developing regenerative medicine approaches for both acute SARS-CoV-2 disease and chronic post-acute sequelae. Publicly available information indicates that GIOCOV was formed in collaboration with TAG Investment Bankers and has described ambitions to seek licensed status in the US, UK, and EU. Based on the limited disclosed pipeline information, GIOCOV is an early-stage private biotech centered on cell therapy applications in infectious disease and post-viral conditions.